论文部分内容阅读
目的:观察不同药物对新诊断2型糖尿病患者的疗效。方法:102例新诊断的2型糖尿病患者随机分为艾塞那肽组(34例)、胰岛素组(34例)和二甲双胍组(34例)。三组患者治疗周期均为16周。分别于治疗前、治疗8周及16周测量糖化血红蛋白(HbAlc)、空腹血糖(FPG)、餐后2 h血糖(2h-PG),低血糖发生率、体重变化情况。结果:三组患者经治疗8周和16周时HbAlc、FPG和2h-PG均降低(P<0.05或0.01),并且艾塞那肽组及胰岛素组血糖下降与二甲双胍组相比差别有统计学意义(P<0.05或0.01)。结论:三种药物对新诊断2型糖尿病患者血糖均能控制良好,艾塞那肽注射液及胰岛素的降糖效果优于二甲双胍,艾塞那肽注射液及二甲双胍减重效果优于胰岛素。
Objective: To observe the effect of different drugs on newly diagnosed type 2 diabetic patients. Methods: A total of 102 newly diagnosed type 2 diabetic patients were randomly divided into exenatide group (34 cases), insulin group (34 cases) and metformin group (34 cases). Three groups of patients were treated for 16 weeks. HbAlc, fasting blood glucose (FPG), 2h postprandial glucose (2h-PG), the incidence of hypoglycemia and body weight were measured before treatment, 8 weeks and 16 weeks after treatment. Results: The levels of HbA1c, FPG and 2h-PG were decreased in the three groups at 8 and 16 weeks after treatment (P <0.05 or 0.01), and there was a statistically significant difference between the exenatide group and the insulin group in the blood sugar drop compared with the metformin group Significance (P <0.05 or 0.01). CONCLUSION: The three drugs have good control of blood glucose in newly diagnosed type 2 diabetic patients. Exenatide injection and insulin have better hypoglycemic effect than metformin. Exenatide and metformin have better weight-loss effects than insulin.